| 词条 | Etodolac |
| 释义 |
| verifiedrevid = 443747089 | IUPAC_name = (RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid | image = Etodolac.svg | width = | image2 = | width2 = | tradename = | Drugs.com = {{drugs.com|monograph|etodolac}} | MedlinePlus = a692015 | licence_EU = | licence_US = | pregnancy_AU = | pregnancy_US = | pregnancy_category = C | legal_AU = S4 | legal_CA = | legal_UK = POM | legal_US = Rx-only | legal_status = | dependency_liability = | routes_of_administration = oral | bioavailability = | protein_bound = 100% | metabolism = liver | elimination_half-life = 7.3 ± 4.0 hours | excretion = renal | IUPHAR_ligand = 7185 | CAS_number_Ref = {{cascite|correct|??}} | CAS_number = 41340-25-4 | ATC_prefix = M01 | ATC_suffix = AB08 | ATC_supplemental = | PubChem = 3308 | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = DB00749 | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID = 3192 | UNII_Ref = {{fdacite|correct|FDA}} | UNII = 2M36281008 | KEGG_Ref = {{keggcite|correct|kegg}} | KEGG = D00315 | ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI = 4909 | ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL = 622 | chemical_formula = | C=17 | H=21 | N=1 | O=3 | molecular_weight = 287.35 g/mol | smiles = CCc2cccc3c1CCOC(CC)(CC(=O)O)c1[nH]c23 | StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI = 1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20) | StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} | StdInChIKey = NNYBQONXHNTVIJ-UHFFFAOYSA-N | synonyms = | density = | melting_point = 145 | melting_high = 148 | melting_notes = | boiling_point = | solubility = 3.92e-02 mg/mL [ALOGPS] | specific_rotation = }} Etodolac is a nonsteroidal anti-inflammatory drug (NSAID). It was patented in 1971 and approved for medical use in 1985.[1] It was approved in the U.S. in 1991.[2] As of 2015 the cost for a typical month of medication in the United States is less than 25 USD.[3] Medical uses{{See also|NSAIDs}}NSAIDs are used for the management of mild to moderate pain, fever, and inflammation. They work by reducing the levels of prostaglandins, which are chemicals that are responsible for pain and the fever and tenderness that occur with inflammation. Etodolac blocks the cyclooxygenase (abbrev. COX) enzymes which form prostanoids, resulting in lower concentrations of prostaglandins. As a consequence, inflammation, pain and fever are reduced. Post-marketing studies demonstrated that etodolac inhibition of cyclooxygenase is somewhat COX-2 selective [4] similar to celecoxib and other "COX-2 inhibitors." Unlike rofecoxib, both etodolac and celecoxib can fully inhibit COX-1 and are designated as having "preferential selectivity" toward COX-2. The R-enantiomer of etodolac is inactive against COX enzymes, but inhibits beta-catenin levels in hepatoma cells.[5] Etodolac is licensed for the treatment of inflammation and pain caused by osteoarthritis and rheumatoid arthritis.[6] InteractionsEtodolac should be avoided by patients with a history of asthma attacks, hives, or other allergic reactions to aspirin or other NSAIDs. Rare but severe allergic reactions have been reported in such individuals. It also should be avoided by patients with peptic ulcer disease or poor kidney function, since this medication can worsen both conditions. Etodolac is used with caution in patients taking blood thinning medications (anticoagulants), such as warfarin (Coumadin), because it increases the risk of bleeding. Patients taking both lithium and etodolac may develop toxic blood lithium levels. Additionally, etodolac has been found to interact with certain anti-depressant medications, such as sertraline or fluoxetine, which can increase risks of stroke, heart attack, and other cardiovascular conditions. Patients also taking ciclosporin (Sandimmune) can develop kidney toxicity. Use in children has not been adequately studied. Etodolac is not habit-forming. NSAIDs should be discontinued prior to elective surgery because of a mild interference with clotting that is characteristic of this group of medicines. Etodolac is best discontinued at least four days in advance of surgery. Etodolac metabolites may also cause a false positive bilirubin result on a urinalysis test. [https://www.ncbi.nlm.nih.gov/pubmed/10442203][7] Pregnancy and nursingEtodolac is generally avoided during pregnancy and nursing. NSAIDs may cause adverse cardiovascular effects in the fetus during pregnancy. [2]Brand namesEtodolac is manufactured by Almirall Limited under the trade name Lodine SR[8] and by Meda Pharmaceuticals under the name Eccoxolac.[9] Generic etodolac is also available.[10] The drug is also sold under several other brand names, including:
References1. ^{{cite book |last1=Fischer |first1=Jnos |last2=Ganellin |first2=C. Robin |title=Analogue-based Drug Discovery |date=2006 |publisher=John Wiley & Sons |isbn=9783527607495 |page=517 |url=https://books.google.ca/books?id=FjKfqkaKkAAC&pg=PA517 |language=en}} 2. ^1 {{cite web|url=http://www.medicinenet.com/etodolac/article.htm|title=etodolac, Lodine (Discontinued): Drug Facts, Side Effects and Dosing|author=Omudhome Ogbru, PharmD|work=MedicineNet}} 3. ^{{cite book|last1=Hamilton|first1=Richart|title=Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition|date=2015|publisher=Jones & Bartlett Learning|isbn=9781284057560|page=7}} 4. ^{{cite journal|last1=Warner|first1=TD|last2=Giuliano|first2=F|last3=Vojnovic|first3=I|last4=Bukasa|first4=A|last5=Mitchell|first5=JA|last6=Vane|first6=JR|title=Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.|journal=Proceedings of the National Academy of Sciences of the United States of America|date=22 June 1999|volume=96|issue=13|pages=7563–8|pmid=10377455|pmc=22126|doi=10.1073/pnas.96.13.7563}} 5. ^{{cite journal|pmid=17275129|year=2007|last1=Behari|first1=J|last2=Zeng|first2=G|last3=Otruba|first3=W|last4=Thompson|first4=MD|last5=Muller|first5=P|last6=Micsenyi|first6=A|last7=Sekhon|first7=SS|last8=Leoni|first8=L|last9=Monga|first9=SP|title=R-Etodolac Decreases Beta-Catenin Levels Along with Survival and Proliferation of Hepatoma Cells|volume=46|issue=5|pages=849–57|doi=10.1016/j.jhep.2006.11.017|pmc=1924913|journal=Journal of Hepatology}} 6. ^BNF 55 - Etodolac 7. ^{{Cite journal|last=Sho|first=Y.|last2=Ishiodori|first2=T.|last3=Oketani|first3=M.|last4=Kubozono|first4=O.|last5=Nakamura|first5=A.|last6=Takeuchi|first6=A.|last7=Morino|first7=A.|last8=Arima|first8=T.|date=July 1999|title=Effects of urinary metabolites of etodolac on diagnostic tests of bilirubin in urine|journal=Arzneimittel-Forschung|volume=49|issue=7|pages=572–576|doi=10.1055/s-0031-1300464|issn=0004-4172|pmid=10442203}} 8. ^{{cite web|url=http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=3581|title=Lodine SR|work=medicines.org.uk}} 9. ^{{cite web|url=http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=12573|title=Eccoxolac|work=medicines.org.uk}} 10. ^BNF 55: Etodolac preparations 11. ^{{cite web|url=http://www.apsen.com.br/bula.php?id_bula=5|title=:: Apsen |work=apsen.com.br}} External links{{Commons category}}
2 : Nonsteroidal anti-inflammatory drugs|Acetic acids |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。